key: cord-0958130-n7uncdcq
authors: Sloan, Brett
title: July 2021: Lisinopril for delayed inflammatory responses to hyaluronic acid fillers after COVID-19 vaccinations
date: 2021-06-08
journal: J Am Acad Dermatol
DOI: 10.1016/j.jaad.2021.04.073
sha: a8f89b95cedf9fd025580303fa792a49b872ff01
doc_id: 958130
cord_uid: n7uncdcq

nan

July 2021: Lisinopril for delayed inflammatory responses to hyaluronic acid fillers after COVID-19 vaccinations Brett Sloan, MD Farmington, Connecticut I n the April 2021 edition of JAAD Case Reports, Munavalli et al 1 reported a case series of 4 patients in whom delayed inflammatory responses to dermal hyaluronic acid filler developed following COVID-19 vaccination. All the patients had the facial filler placed for [8 months prior to the vaccination and significant edema developed at the sites of the filler 24-48 hours after receiving the COVID-19 messenger RNA vaccination. Through a proposed novel mechanism of action, the authors reported a rapid improvement with lisinopril via the inhibition of angiotensin-converting enzyme.

The SAR-CoV-2 spike protein produced from the currently available messenger RNA vaccines interacts with its target ligand, the angiotensin-converting enzyme receptor 2. Alijotas-Reig et al 2 postulated that quiescent filler granulomas can be activated via specific stimulation of the CD8 1 helper T cell type 1 immune response by various triggers, including a viral infection or vaccine, resulting in the clinical findings of a delayed inflammatory response. Through the use of clinical images taken before and after the response as well as a detailed schematic, Munavalli et al 1 demonstrated an impressive response after the use of lisinopril. They illustrated the potential mechanism of delayed inflammatory responses following the accumulation of proinflammatory angiotensin II and certain metabolites occurring downstream in the cutaneous renin-angiotensin system due to the inactivation of angiotensin-converting enzyme receptor 2 by the viral spike protein. Although the authors acknowledged that further studies are needed, they provided a promising treatment option for this unique vaccine-related phenomenon.

Oral angiotensin-converting enzyme inhibitors for treatment of delayed inflammatory reaction to dermal hyaluronic acid fillers following COVID-19 vaccination-a model for inhibition of angiotensin II-induced cutaneous inflammation

Late-onset inflammatory adverse reactions related to soft tissue filler injections

Funding sources: None. IRB approval status: Not applicable. Reprints not available from the author

None disclosed.